

AMENDMENT TO THE CLAIMS

Please amend the claims as indicated below:

1 – 19. (Canceled)

20. (Currently amended) A method of inhibiting angiogenesis in a human individual~~a target tissue~~ comprising the step of administering a Corticotropin Releasing Factor Receptor 2 (CRFR2) agonist to said individual~~target~~ tissue, wherein said CRFR2 agonist inhibits angiogenesis in said individual~~tissue~~.
21. (Previously presented) The method of claim 20 wherein said CRFR2 agonist is selected from the group consisting of urocortin and corticotropin releasing factor.
22. (Currently amended) The method of claim 20, wherein said CRFR2 agonist inhibits angiogenesis in a tissue~~said tissue~~ is selected from the group consisting of heart, brain, pituitary, gonad, kidney, adipose, and gastrointestinal tract tissues.
23. (Previously presented) The method of claims 20 wherein said angiogenesis is inhibited in an individual having a pathophysiological condition selected from the group consisting of cancer and diabetic retinopathy.

24 – 27. (Canceled)